

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Outer carton box / polystyrene box

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Ketexx 100 mg/ml solution for injection
ketamine

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:
Ketamine 100.0 mg (equivalent to 115.3 mg ketamine hydrochloride)

3. PHARMACEUTICAL FORM

Solution for injection

4. PACKAGE SIZE

10 ml
20 ml
50 ml
5 x 10 ml
5 x 20 ml
5 x 50 ml
35 x 10 ml
28 x 20 ml
15 x 50 ml

5. TARGET SPECIES

Dogs, cats, cattle, sheep, goats, horses, guinea pigs, hamsters, rabbits (exclusively kept as pets), rats, mice.

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

For intravenous, intramuscular and intraperitoneal administration.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Withdrawal period:
Cattle, sheep, goats and horses:
Meat and offal: 1 day.
Milk: zero hours.

Not authorised for use in rabbits for human consumption.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP {month/year}
Shelf life after first opening the container: 28 days.
Once broached use by...

11. SPECIAL STORAGE CONDITIONS

12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Alfasan Nederland B.V.
Kuipersweg 9
3449 JA Woerden
The Netherlands

16. MARKETING AUTHORISATION NUMBER(S)

Vm 36408/3000

17. MANUFACTURER’S BATCH NUMBER

Batch {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Glass vials of 10, 20 or 50 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Ketexx 100 mg/ml solution for injection
ketamine

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

Each ml contains:
Ketamine 100.0 mg (equivalent to 115.3 mg ketamine hydrochloride)

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

10 ml
20 ml
50 ml

4. ROUTE(S) OF ADMINISTRATION

IV, IM, IP

5. WITHDRAWAL PERIOD(S)

Withdrawal period:
Cattle, sheep, goats and horses:
Meat and offal: 1 day.
Milk: zero hours.

Not authorised for use in rabbits for human consumption.

6. BATCH NUMBER

Batch {number}

7. EXPIRY DATE

EXP {month/year}
Shelf life after first opening the container: 28 days.

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

B. PACKAGE LEAFLET

PACKAGE LEAFLET:
Ketexx 100 mg/ml solution for injection

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder and manufacturer responsible for batch release:

Alfasan Nederland B.V.
Kuipersweg 9
3449 JA Woerden
The Netherlands

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Ketexx 100 mg/ml solution for injection
ketamine

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each ml contains:

Active substance:

Ketamine 100.0 mg
(equivalent to 115.3 mg ketamine hydrochloride)

Excipient(s):

Benzethonium chloride 0.11 mg

Clear, colourless aqueous solution for injection, practically free from visible particles.

4. INDICATION(S)

The veterinary medicinal product may be used in combination with a sedative for:

- Immobilisation
- Sedation
- General anaesthesia

5. CONTRAINDICATIONS

Do not use in cases of severe hypertension, cardio-respiratory deficiency, or hepatic or renal dysfunction.

Do not use in animals with glaucoma.

Do not use in animals with eclampsia or pre-eclampsia.

Do not use in known cases of hypersensitivity to the active substance or to any of the excipients.

Do not use as a sole anaesthetic agent in any of the target species.

Do not use in ocular surgical interventions.

Do not use for surgical intervention on pharynx, larynx, trachea or bronchial tree, if sufficient relaxation is not ensured by administration of a muscle relaxant (intubation obligatory).

Do not use in animals undergoing a myelogram procedure.

Do not use in cases of pheochromocytoma or untreated hyperthyroidism.
Do not use in cases of head trauma and increased intracerebral pressure.

6. ADVERSE REACTIONS

In anaesthetised animals, mainly during and after the recovery phase, cardio-respiratory disorders (cardiac arrest, hypotension, dyspnoea, bradypnea, pulmonary oedema) associated or not with neurological disorders (convulsions, prostration, tremors) and systemic disorders (hypersalivation, pupillary abnormality) have been observed in rare cases.

Reactions on awakening - ataxia, hypersensitivity to stimuli, excitement - have been rarely and very rarely reported in horses and dogs, respectively.

Salivation has been very rarely reported in cats.

An increase in skeletal muscle tone has been very rarely reported in cats, dogs, horses, rabbits, cattle and goats.

Dose-dependent respiratory depression, which can lead to respiratory arrest, has been very rarely reported in cats, dogs, rabbits, cattle and goats. The combination of respiratory depressants can amplify this effect.

An increase in heart rate has been reported very rarely in cats and dogs. Increased arterial blood pressure with concurrent increased bleeding tendency has been very rarely reported.

In cats and dogs, in very rare cases, the eyes remain open, with mydriasis and nystagmus. Pain during intramuscular injection has been very rarely reported in cats. All adverse reactions and their frequencies come from pharmacovigilance declarations.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon. Alternatively you can report via your national reporting system. For details regarding the national system please contact NCA.

7. TARGET SPECIES

Dogs, cats, cattle, sheep, goats, horses, guinea pigs, hamsters, rabbits (exclusively kept as pets), rats, mice.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Dogs, cats, cattle, horses, guinea pigs, hamsters, rabbits, rats and mice: for slow intravenous and intramuscular administration. In guinea pigs, hamsters, rabbits, rats and mice, the intraperitoneal route can also be used.

Sheep and goats: for slow intravenous administration.

Ketamine should be combined with a sedative.

One dose of 10 mg of ketamine per kg bodyweight corresponds to 0.1 ml of the veterinary medicinal product per kg bodyweight.

Before ketamine is administered, please ensure that the animals are adequately sedated.

The following dosing advices provide possible combinations with ketamine, the concomitant use of other pre-anaesthetics, anaesthetics or sedatives should be subject to a benefit/risk assessment by the responsible veterinarian.

Dogs

Combination with xylazine or medetomidine:

Intramuscular use:

Xylazine (1.1 mg/kg IM) or medetomidine (10 to 30 µg/kg IM) can be used with ketamine (5 to 10 mg/kg i.e. 0.5 to 1 ml/10 kg IM) for short term anesthesia of 25 to 40 minutes. The ketamine dose can be adjusted, depending on the desired duration of surgery.

Intravenous use:

In case of intravenous use, the dose must be reduced to 30 – 50% of the recommended intramuscular dose.

Cats

Combination with xylazine:

Xylazine (0.5 to 1.1 mg/kg IM) with or without atropine is administered 20 minutes before ketamine (11 to 22 mg/kg IM i.e. 0.11 to 0.22 ml/kg IM).

Combination with medetomidine:

Medetomidine (10 to 80 µg/kg IM) can be combined with ketamine (2.5 to 7.5 mg/kg IM i.e. 0.025 to 0.075 ml/kg IM). The dose of ketamine should be reduced as the dose of medetomidine increases.

Horses

Combination with detomidine:

Detomidine 20 µg/kg IV, after 5 minutes ketamine 2.2 mg/kg fast IV (2.2 ml/100 kg IV).

Onset of action is gradual, taking approximately 1 minute to attain recumbency, with duration of anaesthetic effect lasting approximately 10 – 15 minutes.

Combination with xylazine:

Xylazine 1.1 mg/kg IV, followed by ketamine 2.2 mg/kg IV (2.2 ml/100 kg IV)

Onset of action is gradual, taking approximately 1 minute, with duration of anaesthetic effect being variable and lasting 10 – 30 minutes but usually less than 20 minutes.

After injection the horse lays down spontaneously without any further help. If a distinct muscle relaxation is required simultaneously, muscle relaxants can be administered to the recumbent animal, until the horse shows first symptoms of relaxation.

Cattle

Combination with xylazine:

Intravenous use:

Adult cattle can be anaesthetised for short periods with xylazine (0.1 mg/kg IV) followed by ketamine (2 mg/kg IV i.e. 2 ml/100 kg IV). Anaesthesia lasts approximately 30 minutes but can be prolonged for 15 minutes with additional ketamine (0.75 to 1.25 mg/kg IV i.e. 0.75 to 1.25 ml/100kg IV).

Intramuscular use:

Ketamine and xylazine doses should be doubled in case of intramuscular administration.

Sheep and goats

Intravenous use:

Ketamine 0.5 to 7 mg/kg IV i.e. 0.05 to 0.7 ml/10 kg IV depending on the sedative used.

Rabbits and rodents

Combination with xylazine:

Rabbits: xylazine (5-10 mg/kg IM) + ketamine (35-50 mg/kg IM i.e. 0.35 to 0.50 ml/kg IM).

Rats: xylazine (5-10 mg/kg IP, IM) + ketamine (40-80 mg/kg IP, IM i.e. 0.4 to 0.8 ml/kg IP, IM).

Mice: xylazine (7.5-16 mg/kg IP) + ketamine (90-100 mg/kg IP i.e. 0.9 to 1.0 ml/kg IP).

Guinea pigs: xylazine (0.1-5 mg/kg IM) + ketamine (30-80 mg/kg IM i.e. 0.3 to 0.8 ml/kg IM).

Hamsters: xylazine (5-10 mg/kg IP) + ketamine (50-200 mg/kg IP i.e. 0.5 to 2 ml/kg IP).

Dose for maintenance of anaesthesia: when needed, prolongation of effect is possible by repeated administration of an optionally reduced initial dose.

9. ADVICE ON CORRECT ADMINISTRATION

For intramuscular injection in cattle and horses a maximum volume per injection site is 20 ml.

Ketamine can show large inter-individual variation in effect, and therefore dose rates administered should be tailored to the individual animal, dependent on factors such as age, condition, and the depth and duration of anaesthesia required.

The vial can be broached up to 30 times. The user should choose the most appropriate vial size according to the target species to be treated and the administration route.

10. WITHDRAWAL PERIOD(S)

Cattle, sheep, goats and horses:

Meat and offal: 1 day.

Milk: zero hours.

Not authorised for use in rabbits for human consumption.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions. Do not use this veterinary medicinal product after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

Shelf life after first opening the container: 28 days.

12. SPECIAL WARNING(S)

Special warnings for each target species:

For very painful and major surgical interventions, as well as for maintenance of anaesthesia, a combination with injectable or inhalational anaesthetics is indicated.

As muscle relaxation required for surgical procedures cannot be achieved with ketamine alone, additional muscle-relaxants should be used concomitantly.

For improvement of anaesthesia or prolongation of effect, ketamine can be combined with α 2-receptor-agonists, anaesthetics, neuroleptanalgesics, tranquillisers and inhalational anaesthetic agents.

Special precautions for use in animals:

A small proportion of animals have been reported to be unresponsive to ketamine as an anaesthetic agent at normal dosages. Use of premedicants should be followed by a suitable reduction in dosage.

In the cat and dog, the eyes remain open and the pupils dilated. The eyes may be protected by covering with a damp gauze swab or using appropriate ointments.

Ketamine may exhibit pro-convulsant and anti-convulsant properties, and therefore should be used with care in patients with seizure disorders.

Ketamine may increase intracranial pressure and therefore, may not be suitable for patients with cerebrovascular insults.

When used in combination with other products, consult the contraindications and warnings that appear on the relevant data sheets.

The eyelid reflex stays intact.

Twitching, as well as excitation upon recovery, may be possible. It is important that both premedication and recovery should occur in quiet and calm surroundings. To ensure a smooth recovery appropriate analgesia and premedication should be administered, if indicated.

The concomitant use of other pre-anaesthetics or anaesthetics should be subject to a benefit/risk assessment, taking into account the composition of the used medicines and their doses and the nature of the intervention. The recommended doses of ketamine are likely to vary depending on the concomitant pre-anaesthetics and anaesthetics used.

The prior administration of an anticholinergic such as atropine or glycopyrrolate to prevent the occurrence of adverse effects, especially hypersalivation, may be considered after a benefit/risk assessment by the veterinarian.

Ketamine should be used with caution when pulmonary disease is present or suspected.

Animals should be fasted for a period prior to anaesthesia where possible.

In small rodents cooling down should be prevented.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This is a potent drug. Particular care should be taken to avoid accidental self-injection.

People with known hypersensitivity to ketamine or any of the excipients should avoid contact with the veterinary medicinal product.

Avoid contact with the skin and eyes. Wash any splashes from skin and eyes immediately with large amounts of water.

Adverse effects on the foetus cannot be excluded. Pregnant women should avoid handling the veterinary medicinal product.

In case of accidental self-injection or if symptoms develop after ocular/oral contact, seek medical advice immediately and show the package leaflet or the label to the physician, but DO NOT DRIVE, as sedation may occur.

Advice to doctors: Do not leave patient unattended. Maintain airways and give symptomatic and supportive treatment.

Use during pregnancy and lactation:

Ketamine passes the blood placenta barrier very well to enter the foetal blood circulation in which 75 to 100% of the maternal blood levels can be reached. This partially anaesthetises neonates delivered by caesarean section. The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only according to the benefit/risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

Neuroleptics, tranquillisers, cimetidine and chloramphenicol increase the anaesthetic effect of ketamine (also see the section on Special warnings for each target species). Barbiturates, opiates and diazepam may prolong time to recovery.

Effects may be cumulative. A decrease of the dose of one or both agents may be necessary.

There is a possibility of an increased risk of cardiac arrhythmia when ketamine is used in combination with thiopental or halothane. Halothane prolongs the half-life of ketamine.

Simultaneous intravenous administration of a spasmolytic agent may provoke a collapse.

Theophylline, when given with ketamine, may provoke an increase of epileptic crises. When detomidine is used together with ketamine, the recovery is slower than when ketamine is used alone.

Overdose (symptoms, emergency procedures, antidotes):

In case of overdose CNS effects (e.g. seizures), apnoea, cardiac arrhythmia, dysphagia and respiratory depression or paralysis may occur.

If necessary, suitable artificial aids to maintain ventilation and cardiac output should be used until sufficient detoxification has taken place. Pharmacological cardiac stimulants are not recommended, unless no other supportive measures are available.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product should not be mixed with other veterinary medicinal products.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

{DD/MM/YYYY}

15. OTHER INFORMATION

Brown type I glass vials containing 10 ml, 20 ml and 50 ml product, closed with a bromobutyl rubber stopper and aluminium cap.

Pack sizes:

Carton box holding 1 vial of 10 ml, 20 ml or 50 ml

Carton box holding 5 vials of 10 ml, 20 ml or 50 ml


Polystyrene box holding 35 vials of 10 ml

Polystyrene box holding 28 vials of 20 ml

Polystyrene box holding 15 vials of 50 ml

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.



Approved: 10 June 2022